Eli Lilly’s Mounjaro is considerably more practical than Novo Nordisk’s Ozempic in producing weight reduction in sufferers with chubby or weight problems, a brand new real-world examine discovered.
In an evaluation of 18,000 sufferers, these taking Mounjaro had been thrice extra probably than these taking Ozempic to realize 15% weight reduction, in line with the examine by Truveta Analysis, which analyzes de-identified affected person information from a collective of well being methods. After one 12 months of remedy, the sufferers taking Mounjaro misplaced a mean 15.2% of their…
Grasp your cash.
Subscribe to MarketWatch.
Get this text and all of MarketWatch.
Entry from any gadget. Anyplace. Anytime.
Already a subscriber?
Log In